Search PubMed⌕ Search

Biomedical subjects

M Benbunan

Publications and source records attributed to M Benbunan.

69 records · Page 4Linked to original sources
PubMed1985

Content of red blood-cell sialic acid in BW 35 blood donors. Relation to magnesium concentration and pyruvate kinase activity.

Previous studies have shown that the concentration of red blood cell (RBC) magnesium is significantly lower in subjects carrying an HLA-BW 35 antigen (p less than 0.001) than in non-carriers. As this finding might be related to modifications of the RBC membrane sialoglycoconjugates, RBC sialic acid was comparatively determined in BW 35+ and BW 35- subjects. Pyruvate-kinase activity mean RBC volume, and reticulocyte count have also been determined in order to estimate whether some significant variations in the level of these age markers could be detected between the HLA BW 35+ and BW 35- subjects. A significant negative correlation between sialic acid and RBC magnesium concentrations was observed for the whole population tested (n 57, p less than 0.005), 61% of the BW 35+ and only 25% of the BW 35- individuals having sialic acid values above, and magnesium values below the overall mean (p less than 0.01). The variance of mean RBC volume was also larger for the BW 35+ group. Other determinations did not show any significant variations, suggesting that the results are not related to RBC age.

Adult↗
PubMed1985

Complete correction of Glanzmann's thrombasthenia by allogeneic bone-marrow transplantation.

Allogeneic bone marrow transplantation (BMT) successfully corrected type I thrombasthenia in a 4-year-old boy. The donor was his HLA-A, B and D identical 14-year-old brother who was heterozygous for thrombasthenia. A first transplant after conditioning with cyclophosphamide and thoracoabdominal irradiation was rejected, but a second transplant using CCNU, cyclophosphamide, procarbazine and horse antihuman thymocyte globulin in the preparative regimen was successful. Engraftment was proven by studies of platelet membrane antigens, PLA1 and glycoprotein IIb/IIIa complex and by platelet function studies. Haemorrhagic manifestations completely disappeared; platelet membrane markers and clot retraction returned promptly to normal values, and platelet aggregation tests more slowly. Twenty-four months after bone-marrow transplant, the patient was well with mild chronic hepatic graft versus host disease. BMT therefore appears to be a possible treatment for severe inherited platelet disorders.

Blood Platelet Disorders↗
PubMed1976

[Lessons drawn from granulocyte transfusions in the treatment of infections complicating aplasia induced by anti-leukemic chemotherapy].

The authors report the results of leukocyte transfusions of white cells obtained by sedimentation from donors with chronic myeloid leukemia, and by a continuous output cell separator used in healthy donors. The percentage of therapeutic efficacy of these two techniques is respectively, 62 and 78%. Among the factors affecting transfusion efficacy, the dose of injected leukocytes, the immunological compatibility and the functional value of the injected cells, appear of major importance. A qualitative study of the polymorphs in chronic myeloid leukemia, assessed by reduction with tetrazolium nitro-blue (N.B.T.) after ingestion of latex particles, proved normal when studied in vivo in the recipient. The mode of action of transfused leukocytes is then discussed.

Adult↗
PubMed1975

[Treatment of bone marrow aplasia by allogenic bone marrow grafts].

Three patients with severe aplastic anemia were treated by bone marrow transplantation using the method described by Santos and Thomas. Two of the patients, both successfully grafted have survived for more than 5 and 6 months respectively. Chimerism was proved by cytogenetic analysis and erythrocytic phenotypes. In one case, a severe graft versus host reaction was cured with ATG and prednisone. Graft rejection in the third case was related to the immunisation caused by many previous transfusions. Although bone marrow grafting is limited by the necessity of using a matched sibling as donor, its success this far is very encouraging and represents a new hope for the treatment of aplastic anemia.

Adolescent↗